Clinical Research
Copyright ©The Author(s) 2003.
World J Gastroenterol. Aug 15, 2003; 9(8): 1808-1814
Published online Aug 15, 2003. doi: 10.3748/wjg.v9.i8.1808
Figure 5
Figure 5 Telomerase activity after treated with PS-ODN in P3 cell line (1: positive control; 2: negative control; 3-6: 100 μmol/ L, 31. 60 μmol/L, 10 μmol/L, 3.16 μmol/L PS-ODN1 groups; 7-10: 3.16 μmol/L,10 μmol/L, 31.60 μmol/L, 100 μmol/L PS-ODN2 group; 11: 100 μmol/L PS-ODN3 group; 12: 100 μmol/L PS-ODN4 groups).